&w=3840&q=100)
Sun Pharma's ILUMYA delivers positive psoriatic arthritis trial results
The Phase 3 INSPIRE-1 and INSPIRE-2 studies evaluated the efficacy and safety of ILUMYA over a 24-week period. According to the company, both trials achieved statistically significant improvements in ACR20 response rates—a standard measure of arthritis treatment effectiveness—compared with placebo at Week 24.
INSPIRE-1 included patients with prior exposure to anti-TNF therapies, while INSPIRE-2 focused on anti-TNF naïve patients. More than 800 adult participants were enrolled across clinical sites in the US, Europe, and Asia. ILUMYA was administered at Week 0 and every 12 weeks thereafter, with no induction dose.
Consistent safety profile supports regulatory case
Sun Pharma stated that the safety outcomes in the psoriatic arthritis trials were consistent with ILUMYA's established safety profile from earlier studies in plaque psoriasis. No new safety signals were identified.
ILUMYA is currently approved in the US and other countries for the treatment of moderate-to-severe plaque psoriasis in adults. Its use in psoriatic arthritis remains investigational and has not yet been evaluated by regulatory authorities.
Detailed results from the INSPIRE studies will be presented at upcoming medical conferences and submitted for publication in peer-reviewed journals.
Targeting IL-23 in chronic inflammatory pathways
ILUMYA is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), thereby inhibiting inflammatory pathways associated with chronic autoimmune conditions. Common adverse reactions reported in previous studies include upper respiratory infections, injection-site reactions, and diarrhoea. The drug carries warnings related to hypersensitivity, infections, and tuberculosis risk.
Psoriatic arthritis affects an estimated 2.4 million people in the United States. Approximately one-third of psoriasis patients may develop the joint condition, though many cases remain undiagnosed.
Strategic pipeline strengthens global presence
Sun Pharma is India's largest pharmaceutical company and one of the world's leading generic drug manufacturers. The company operates in over 100 countries and has a growing specialty portfolio in dermatology, ophthalmology, and onco-dermatology.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
3 hours ago
- The Hindu
Weight regain begins 8 weeks after stopping anti-obesity drugs, says study
A review of data from clinical trials of weight-loss drugs has concluded that weight regain begins about eight weeks after stopping these medications, and continues up to 20 weeks, before stabilising at about 26 weeks. The paper 'Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications' published in BMC Medicine, an open access, transparent peer-reviewed general medical journal, also observed that at 52 weeks, the subjects of the trial still weighed less than they did before starting medication, but the weight loss was reduced compared to when they were actively taking the drugs. 11 clinical trials The researchers Han Wu et al, from the Department of Endocrinology and Metabolism, Peking University People's Hospital, China, analysed data from 11 clinical trials with 1,573 people taking anti-obesity medication. These medications included: GLP-1 receptor agonists (such as semaglutide, liraglutide), orlistat, naltrexone-bupropion, and phentermine-topiramate. Randomised controlled trials of anti-obesity medications conducted in the population for at least four weeks and followed up for four or more weeks after discontinuation were included. The review sought to examine the post-trial period when the drugs stop, estimate what happens to the weight of these patients, how much weight is regained, how soon do they begin to regain weight and the impact of lifestyle factors on weight. The researchers observed that people who lost more weight during treatment were more likely to regain weight, even if they continued lifestyle interventions (including diet and exercise). Those who started with a lower body mass index (BMI), meaning they were less overweight, showed more weight regain after stopping than those with higher BMI. Interestingly, people taking GLP-1-related drugs experienced more weight regain after stopping than those on other drugs, they reported in the paper. Different weight regain was observed in subjects with different characteristics, the researchers said, adding that studies with a longer follow-up duration are required to further investigate the potential factors associated with weight change after discontinuation of treatment. Hope to many 'This is an interesting study with robust meta analyses, but similar results have been shown in many other trials too,' says Dr. Nanditha, consultant diabetologist, Dr. A. Ramachandran's Diabetes Hospitals, Chennai. 'Any intervention, either when you step down or discontinue, will result in weight gain, even if it is lifestyle modifications.' However, it is important to see the usefulness of these drugs in the context of the obesity epidemic. Obesity, originally, was looked upon as a risk factor, but is now considered a disease by itself. 'Earlier, we did not have many tools to treat it, now these drugs are providing hope to people who can lose weight without surgery. What is clear is that the regain will not take you back to the baseline weight, so while expensive, these drugs should be considered an investment, because the benefits go beyond weight loss,' she said. It may be remembered that another study, published recently in the journal Obesity, showed that semaglutide and tirzepatide — injectable GLP-1 drugs for obesity — produce lower weight loss in a real-world setting, as compared to during the clinical trial, because patients discontinue treatment or use lower maintenance dosages.
The Hindu
6 hours ago
- The Hindu
COVID-19 cases surged during May-end, declined after June 13, Rajya Sabha told
A surge in Covid-19 cases was witnessed during the end of May this year, which peaked around June 13 after which the trajectory of cases declined significantly in the country, Minister of State for Health, Prataprao Jadhav, told the Rajya Sabha on Tuesday (June 22, 2025). As reported by States and UTs, most of the cases were mild in nature and resolved on their own, Mr. Jadhav said in a written reply in the Upper House. The World Health Organization (WHO) on May 28 issued a Disease Outbreak News (DON) wherein it highlighted that since mid-February, global SARS-CoV-2 increased activity, particularly in countries in the Eastern Mediterranean, Southeast Asia, and Western Pacific regions, including India. The report also pointed out that while since early 2025, global SARS-CoV-2 variant trends have been shifting slightly and reporting of NB.1.8.1 variant (Nimbus) is increasing, the overall increase in Covid-19 is broadly consistent with levels observed during the same period of the previous year, Mr. Jadhav said. As per WHO risk assessment, the available evidence on NB.1.8.1 and XFG does not suggest additional public health risks relative to the other currently circulating Omicron descendent lineages. "By the end of May, a surge in Covid-19 trajectory of cases was also witnessed in the country, which peaked around June 13. Since then, the trajectory of Covid-19 cases in the country has declined significantly,' Jadhav said. The Ministry of Health and Family Welfare on May 29 issued an advisory to all the states and UTs to undertake a review of hospital preparedness with special focus on the availability of diagnostics, essential drugs, PPEs, isolation beds, medical oxygen, ICU and ventilator supported beds. The States and UTs were also requested to closely follow the trend of Influenza Like Illness/Severe Acute Respiratory Illness while undertaking testing for Covid-19 as per this ministry's 'operational guidelines for revised surveillance strategy in context of Covid-19', Mr. Jadhav said. They were also advised to refer to an adequate number of samples for whole genomic sequencing, the Minister said. The Ministry also urged all the states and UTs to undertake mock drills to assess preparedness and operational readiness of all the health facilities, including requisite infrastructure, logistics (drugs and equipment) as well as healthcare workforce, he added.
News18
7 hours ago
- News18
Covid cases surged during end May, declined after June 13: Govt
Last Updated: New Delhi, Jul 22 (PTI) A surge in Covid-19 cases was witnessed during the end of May this year, which peaked around June 13 after which the trajectory of cases declined significantly in the country, Minister of State for Health, Prataprao Jadhav, told the Rajya Sabha on Tuesday. As reported by states and UTs, most of the cases were mild in nature and resolved on their own, Jadhav said in a written reply in the Upper House. The World Health Organization (WHO) on May 28 issued a Disease Outbreak News (DON) wherein it highlighted that since mid-February, global SARS-CoV-2 increased activity, particularly in countries in the Eastern Mediterranean, Southeast Asia, and Western Pacific regions, including India. The report also pointed out that while since early 2025, global SARS-CoV-2 variant trends have been shifting slightly and reporting of NB.1.8.1 variant (Nimbus) is increasing, the overall increase in Covid-19 is broadly consistent with levels observed during the same period of the previous year, Jadhav said. As per WHO risk assessment, the available evidence on NB.1.8.1 and XFG does not suggest additional public health risks relative to the other currently circulating Omicron descendent lineages. 'By the end of May, a surge in Covid-19 trajectory of cases was also witnessed in the country, which peaked around June 13. Since then, the trajectory of Covid-19 cases in the country has declined significantly," Jadhav said. The Ministry of Health and Family Welfare on May 29 issued an advisory to all the states and UTs to undertake a review of hospital preparedness with special focus on the availability of diagnostics, essential drugs, PPEs, isolation beds, medical oxygen, ICU and ventilator supported beds. The states and UTs were also requested to closely follow the trend of Influenza Like Illness/Severe Acute Respiratory Illness while undertaking testing for Covid-19 as per this ministry's 'operational guidelines for revised surveillance strategy in context of Covid-19', Jadhav said. They were also advised to refer to an adequate number of samples for whole genomic sequencing, the minister said. The ministry also urged all the states and UTs to undertake mock drills to assess preparedness and operational readiness of all the health facilities, including requisite infrastructure, logistics (drugs and equipment) as well as healthcare workforce, he added. PTI PLB ARI view comments First Published: July 22, 2025, 19:30 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
